chevron_leftBack
As of 13 June 2026, Alaunos Therapeutics, Inc. has a market cap of $5.84M USD, ranking #43829 globally and #5593 in the United States.
It ranks #3887 in the Healthcare sector, and #766 in the Biotechnology industry.
Key Stats
Market Cap
$5.84MUSD
Enterprise Value
$4.77MUSD
Revenue (TTM)
$5.0KUSD
EBITDA (TTM)
-$4.22MUSD
Net Income (TTM)
-$4.28MUSD
PS Ratio
1231.9
PB Ratio
2.8
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Holger Weis
open_in_new
Employees
1
Founded
1998
Website
alaunos.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -5.2% | -12% | -18% | -12% | -8.7% | 0.2% |
News
Loading...
TCRT Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
TCRT
Alaunos Therapeutics Inc
ISIN: US98973P3091
Shares Out.:
Shares Outstanding:
2.442M1
Shares Float:
2.055M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
2.46 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Alaunos Therapeutics, Inc.
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops small molecules to treat obesity and other metabolic disorders. The company develops an oral obesity compound that addresses shortcomings of injectable GLP-1 receptor agonists, including preserving lean muscle mass. It also evaluates ALN1001 and related derivatives on lipid deposition and gene expression. In addition, the company develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is headquartered in Houston, Texas.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: AMGN
|
$182.42B
3M%
|
23.9
|
|
NASDAQ: GILD
|
$159.92B
3M%
|
19.0
|
|
NASDAQ: NTRA
|
$27.6B
473K%
|
-
|
|
NYSE: IQV
|
$26.3B
450K%
|
20.0
|
|
NASDAQ: UTHR
|
$25.03B
429K%
|
20.4
|
|
NASDAQ: MRNA
|
$18.13B
310K%
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
EBR: ARGX
|
$47.84B
819K%
41.39B EUR
|
39.9
|
|
KRX: 207940
|
$44.84B
768K%
68.19T KRW
|
35.5
|
|
ASX: CSL
|
$42.36B
725K%
60.27B AUD
|
29.3
|
|
SIX: LONN
|
$42.3B
724K%
33.71B CHF
|
37.2
|
|
KRX: 068270
|
$28.11B
481K%
42.76T KRW
|
43.8
|
|
NASDAQ: BNTX
|
$25.69B
440K%
|
-
|
chevron_leftBack